Purpose of this study is to evaluate safety and activity of perifosine and sorafenib combination therapy in patients with lymphoproliferative diseases. Perifosine and sorafenib combination therapy is feasible with manageable toxicity and demonstrates promising activity in patients with Hodgkin lymphoma.

The predictive value of pERK and pAKT should be confirmed in a larger patient cohort.

READ FULL ARTICLE Curated publisher From Mdlinx